ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer
Phase 3 trial finds that next-generation KRAS G12C inhibitor divarasib significantly reduced risk of cancer progressing and death
Patients receiving divarasib lived a median of approximately 18 months
Fewer severe treatment-related side effects were reported with divarasib
ABSTRACT: LBA5
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly...
ESMO 2026: UT MD Anderson highlights innovative approaches to monitor, prevent and treat cancer
ABSTRACTS: 3438O, 4244RO, 540RO, 2490P
Researchers at The University of Texas MD Anderson Cancer Center presented new findings at the...
ESMO 2026: Immunotherapy combination extends survival in advanced endometrial cancer
Patients receiving durvalumab plus olaparib lived almost one year longer than patients treated with chemotherapy alone
Study...
Targeted antibody improves outcomes for patients with advanced lung cancer who have faced treatment resistance
Phase 3 HARMONi study evaluated ivonescimab plus chemotherapy for patients with EGFR-mutant lung cancer whose tumors stopped responding to treatment
This combination cut the risk of cancer progression nearly in half compared to chemotherapy alone
Patients on ivonescimab-chemotherapy treatment lived more than two months longer without their cancer worsening
Patients with EGFR-mutant non-small cell lung cancer...
Biomarkers may help identify lung cancer patients who benefit most from perioperative immunotherapy
Phase 3 CheckMate 77T trial demonstrated improved outcomes from immunotherapy given before and after surgery, called perioperative immunotherapy...
Novel CAR T cell therapy offers promising option for hard-to-treat kidney cancer
Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer, and patients who progress on standard therapies have limited...
Experimental cell therapy delivers encouraging results for patients with rare, potentially fatal brain infection
No approved treatments exist for progressive multifocal leukoencephalopathy (PML), a serious neurological condition caused by the JC virus...
Lower trust in doctors and health agencies linked to gaps in awareness that HPV causes cervical cancer
U.S. adults with less trust in government health agencies or doctors were less likely to be aware that HPV causes cervical cancer, study...
EHA: Oral combination shows high response rates in patients with hard-to-treat acute myeloid leukemia
Relapsed or refractory acute myeloid leukemia (AML) represents one of the most challenging hematologic cancers
The menin inhibitor revumenib...
ASCO: Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer
Sunvozertinib is an oral pill targeting specific forms of mutant EGFR, made by Dizal Pharmaceutical
Phase 3 WU-KONG28 trial evaluated...